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M A J O R A R T I C L E
Pneumococcal Conjugate Vaccine Given Shortly
After Birth Stimulates Effective Antibody
Concentrations and Primes Immunological
Memory for Sustained Infant Protection
J. Anthony G. Scott,1,2 John Ojal,1 Lindsey Ashton,3 Anne Muhoro,1 Polly Burbidge,3 and David Goldblatt3
1Kenya Medical Research Institute–Wellcome Trust Research Programme, Kilifi, Kenya; 2Nuffield Department of Clinical Medicine, University of Oxford,
Oxford, United Kingdom; and 3University College London Institute of Child Health, London, United Kingdom
Background. In developing countries, newborn immunization with pneumococcal conjugate vaccines (PCVs)
could protect young infants who are at high risk of invasive pneumococcal disease (IPD) but might lead to immune
tolerance.
Methods. In a randomized trial, young infants received 7-valent PCV at 6, 10, and 14 weeks (Expanded
Programme on Immunization [EPI] group) or 0, 10, and 14 weeks (newborn group). Safety was monitored actively
at 2–7 days and then passively. Serum samples obtained at birth and 6, 10, 14, 18, 36, and 37 weeks were assayed by
enzyme-linked immunosorbent assay for anticapsular immunoglobulin G concentration and avidity. Infants were
boosted with either 7-valent PCV or one-fifth dose of pneumococcal polysaccharide vaccine at 36 weeks.
Nasopharyngeal swab samples were obtained at 18 and 36 weeks.
Results. Three-hundred neonates and young infants were enrolled. Newborn vaccination was well tolerated.
Adverse events occurred equally in each group; none was related to immunization. One infant, immunized at birth,
died of unrelated neonatal sepsis. At 18 weeks, protective concentrations ($0.35 lg/mL) were achieved against each
serotype by $87% of infants with no significant differences between groups. Geometric mean concentrations were
higher in the EPI group for serotypes 4, 9V, 18C, and 19F at 18 weeks and for serotype 4 at 36 weeks. Avidity was
greater in the newborn group for serotypes 4, 6B, and 19F at 18 weeks and for serotype 19F at 36 weeks. Booster
responses and vaccine-type/nonvaccine-type carriage prevalence did not differ between groups.
Conclusions. PCV was safe, immunogenic, and primed for memory when given at birth. There was no evidence of
immune tolerance. Vaccination beginning at birth offers an alternative to control IPD in vulnerable young infants.
The pneumococcus causes 14.5 million episodes of seri-
ous illness in children aged ,5 years worldwide and
826 000 deaths annually [1]. More than half of these
deaths occur in African children. Trials in South Africa
and The Gambia have shown pneumococcal conjugate
vaccine (PCV) to be highly efficacious against invasive
pneumococcal disease (IPD) in human immunodefi-
ciency virus (HIV)–positive and HIV-negative children
[2] and against radiologically confirmed pneumonia and
all-cause mortality [3]. The World Health Organization
(WHO) has recommended that developing countries
with high childhood mortality should introduce PCV
into their routine immunization schedules [4].
In the industrialized world, IPD is uncommon in
neonates but peaks in the second year of life [5]. In The
Gambia, incidence peaks at age 6–11 months [6], but the
burden of disease in young infants (aged ,60 days) is
notable. In a study of sepsis in young infants in 4 de-
veloping countries, the pneumococcus accounted for
17% of cases [7]. In Kenya, the IPD incidence is highest
in young infants [8] and, among infants and young
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children (,2 years) targeted for vaccine, 15% of IPD episodes
occurs during the first 2 months of life. The WHO recommends
immunization with PCV at either 6, 10, and 14 weeks and 2, 3,
and 4 months [4], but these schedules cannot protect young
infants. In addition, the timing of first vaccination is often
delayed [9], which further widens the gap of vulnerability.
To protect young infants, there are 2 alternative approaches:
maternal immunization or newborn immunization. Newborn
immunization with protein-conjugated Haemophilus influenzae
type b (Hib) vaccine has raised a concern that vaccine given at
birth could induce tolerance to subsequent doses of the same
vaccine [10]. In this study, we report a prospective randomized
schedule trial examining the safety and immunogenicity of
7-valent PCV (7vPCV) when the first dose was delivered within
72 hours of birth. The primary endpoint was immunogenicity at
18 weeks of age. We also assessed antibody function by assaying
avidity and by monitoring the effect of vaccine on nasopharyn-
geal carriage. We investigated immune memory using a booster
dose administered at 9 months of age.
METHODS
Study Setting and Design
This open-label randomized schedule trial took place at Kilifi
District Hospital among residents of the Kilifi Health and De-
mographic Surveillance System (KHDSS) area, a rural pop-
ulation of 240 000 on the coast of Kenya [11]. Women attending
antenatal clinic in their last trimester who had negative results
on an HIV test were encouraged to enroll their children at birth.
Neonates delivered at Kilifi District Hospital were enrolled
within 24 hours of birth; those born at home were included up
to 72 hours following delivery. Exclusion criteria were as follows:
temporary residence in the KHDSS area; participation in an-
other trial; suspected immune deficiency; congenital abnor-
mality; sickness requiring hospitalization; birth weight,2500 g;
heart rate .150 or ,100/minute; respiratory rate .60 or
,35/minute; axilla temperature of.37.5 or,35.5C. The birth
weight threshold excluded 20% of all newborns and was therefore
reduced to 2000 g after 199 babies had been recruited.
Participants were divided evenly into 8 groups on 3 criteria in
a factorial design: Expanded Programme on Immunization
(EPI) vaccine schedule, compared with newborn schedule; ad-
ditional blood sampling at 10 weeks, compared with 14 weeks;
and pneumococcal polysaccharide vaccine (PPV), compared
with PCV booster. Three hundred allocations were designated at
the outset, and each participant was assigned a group at enrol-
ment by automatic computer application of a random number
to all residual allocations.
The EPI group received 7vPCV at 6, 10, and 14 weeks of age.
The newborn group received 7vPCV at 0, 10, and 14 weeks of
age. All neonates were given BCG and oral polio vaccine at birth
and pentavalent vaccine (diphtheria-tetanus-pertussis/hepatitis
B/Hib) and oral polio vaccine at 6, 10, and 14 weeks according to
the EPI schedule. At 36 weeks of age, each infant received
a booster of either 7vPCV or a 20% fractional dose (0.1 mL) of
23-valent PPV concomitantly with measles vaccine. Cord blood
samples were obtained, and venous samples were collected at 18,
36, and 37 weeks and at either 10 or 14 weeks of age. Blood
samples were obtained from EPI group infants at 6 weeks. Na-
sopharyngeal swab samples were obtained at 18 and 36 weeks of
age. Written informed consent was obtained from each mother,
and the study was approved by the Kenya Medical Research
Institute and WHO (Sub-Committee for Research Involving
Human Subjects) Ethical Review Committees.
The 7vPCV vaccine was Prevnar (Wyeth Vaccines), contain-
ing 2 lg of capsular polysaccharides of serotypes 4, 9V, 14, 18C,
19F, and 23F and 4 lg of serotype 6B conjugated to 0.5 mg of
the carrier protein CRM197 adsorbed on aluminum phosphate.
The PPV was a 23-valent unconjugated pneumococcal poly-
saccharide vaccine (Pneumovax; Sanofi Pasteur) containing
25 lg of each polysaccharide. Vaccines were donated by Wyeth
Vaccines.
Infants were monitored clinically for 30 minutes after the first
dose of 7vPCV and were reassessed by the study doctor after 7
days (after 2 days for the first 54 infants). Standard vaccine-
related symptoms and signs were elicited and recorded. Parents
were given 24-hour access to the pediatric research clinic and
advised to return at any time during the first 37 weeks of life
with any potential adverse reaction. At each illness visit, the
attending physician completed an adverse event form and des-
ignated the illness as an illness unrelated to immunization,
a minor adverse event, or a severe adverse event—an illness
severe enough to require hospital admission. All severe adverse
events were reviewed by the investigators and the Data Safety and
Monitoring Board to evaluate their relationship to vaccine. The
KHDSS was used to follow long-term mortality up to July 2009.
Blood samples were refrigerated and transported within 6
hours to the laboratory, where the serum was separated and
stored at 280C. Serum samples were assayed for immuno-
globulin G (IgG) antibodies to 7 individual capsular poly-
saccharides in the WHO reference laboratory for pneumococcal
serology at University College London Institute of Child Health
using enzyme-linked immunosorbent assay (ELISA) following
adsorption with cell wall polysaccharide and 22F polysaccharide,
as described previously [12, 13]. Avidity for antibody to sero-
types 4, 6B, 14, and 19F was measured by modification of an assay
developed for anti-Hib avidity by incorporating an ammonium
thiocyanate elution step into the pneumococcal ELISA [14].
Nasopharyngeal samples were collected using rayon-tipped
flexible wire swabs and stored in skimmed milk–tryptone–
glucose–glycerol medium and inoculated the same day onto
gentamicin (2.5 lg/mL) blood agar [15]. The presence of
664 d CID 2011:53 (1 October) d Scott et al
pneumococci was confirmed by means of optochin susceptibility.
Up to 4 morphologically distinct colonies were serotyped, per
swab, by quelling reaction [16]. All laboratory scientists were blind
to the vaccine schedule and booster group allocations.
Statistical Analysis
Geometric mean concentrations (GMCs) and 95% confidence
intervals were calculated for pneumococcal serotype-specific
antibodies in each vaccine schedule group. Differences in means
of log-transformed concentrations were analyzed by Welch test
at 18 and 36 weeks. This approach was repeated with antibody
avidity. For each serological analysis, results from all available
serum samples (or serum pairs) were included. The pro-
portion of samples at or above the putative protective threshold,
0.35 lg/mL [17], in each vaccine group was tested using v2.
Secondary analyses were performed at the higher threshold of
1.00 lg/mL. Analysis of variance was performed for the vaccine
group and booster group at 36 weeks on log-transformed ratios
of the 37/36-week concentrations. The inhibitory effect of
maternal antibodies, specified as quintiles of cord blood con-
centration, was examined by analysis of variance of the 18-week
GMCs. Linear regression of the serotype-specific GMCs across
quintiles was fitted using variance-weighted least squares (VWLS)
to account for within-quintile variance.
To estimate the immediate protective effect of newborn
vaccine, we assumed that vaccine-induced antibody in the
newborn group declined at a constant rate that could be esti-
mated from the decline of maternally derived antibody in the
EPI group between 0 and 6 weeks of age. By applying this rate to
the cord blood concentrations in the newborn group, we esti-
mated the mean ratio increase attributable to a birth dose by
referencing the observed concentrations at 10 weeks; to estimate
95% confidence intervals, we incorporated the sum of the
standard errors of the mean concentrations at birth and 10
weeks and of the mean decay rate.
Children were classified as vaccine-serotype carriers if pneu-
mococci of serotypes 4, 6B, 9V, 14, 18C, 19F, or 23F were isolated.
Children with other serotypes were classified as nonvaccine-
serotype carriers. Carriers of multiple serotypes could be included
in each group. The primary endpoints were the associations
between vaccine group and vaccine-serotype carriage at 18
weeks, and between vaccine group and nonvaccine-serotype
carriage at 36 weeks. The study sample size was chosen to de-
tect, with 90% power, a 12% difference in vaccine-serotype
carriage at 18 weeks against a baseline of 16%. This sample size
also provided .90% power to observe a difference of$30% in
the GMC of antibody concentrations in the 2 schedule groups.
An interim analysis of antibody concentrations was per-
formed on 18-week serum samples for the first 30 vaccinees, to
screen for immune tolerance. The International Standard Ran-
domized Controlled Trial Number was 52829313.
RESULTS
Between 15 December 2004 and 30 August 2007, 300 neonates
were recruited within 72 hours of birth and randomized in equal
numbers to the EPI group and the newborn group (Figure 1).
The 2 groups were similar in sex, mother’s age, birth weight, and
baseline vital signs (Table 1). During individual follow-up over 9
months, 26 EPI group and 32 newborn group participants were
withdrawn from the study, died, or were lost to follow-up
(Figure 1).
There were no significant differences in the safety ob-
servations in the 2 groups. Thirty minutes after first immuni-
zation with 7vPCV, 8 children in the EPI group (5.3%) and 10 in
the newborn group (6.7%) had an axillary temperature
$37.5C. At the first follow-up visit, 1 child had swelling at the
immunization site and 1 child in the EPI group (0.8%) and 5
children in the newborn group (3.4%) had a temperature
$37.5C; 1 child from each group had a temperature $38.0C.
Between birth and 9 months of age, there were 177 adverse
events and 38 serious illnesses requiring hospitalization in the
EPI group and 167 adverse events and 32 serious illnesses re-
quiring hospitalization in the newborn group, none of which
was related to vaccination. One child in the newborn group died
at home on day 3 of life without presenting to the research clinic.
A postmortem questionnaire was conducted 40 days later. Three
pediatricians who reviewed the evidence independently con-
cluded that the cause of death was neonatal sepsis unrelated to
immunization. During extended follow-up through the de-
mographic surveillance, 1 additional death was detected, in an
EPI group child aged 44 weeks.
At 18 weeks of age, the proportion of infants who had attained
the protective threshold (0.35 lg/mL) was$87% for antibodies
to all vaccine serotypes, and there were no significant differences
in these proportions by vaccine group (Table 2). However, the
GMCs of anticapsular IgG were higher in the EPI group than in
the newborn group for 4 of 7 serotypes (Figure 2A). By 36 weeks,
these differences had disappeared, except for serotype 4, in
which the GMC remained greater in the EPI group (Figure 2B).
The proportion of infants with anticapsular IgG above the
protective threshold at 36 weeks was significantly higher in the
EPI group (91% vs 80%; P, .05) for serotype 4 only (Table 2).
Results at 10 and 14 weeks are shown in Supplementary Table 1.
A higher threshold of$1.0 lg/mL may be more appropriate for
high-transmission settings in developing countries and for
protection against nonbacteremia pneumonia; the proportions
achieving this were indistinguishable at 36 weeks (Supplemen-
tary Table 2), but at 18 weeks they were greater among the EPI
group for 3 serotypes. GMCs for serum samples collected at all
time points are shown in Supplementary Table 3.
At 18 weeks of age, the geometric mean avidity index for
3 (4, 6B, 19F) of the 4 serotypes assayed was significantly
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greater in the newborn group than in the EPI group (Figure 3).
At 36 weeks, the geometric mean avidity index was significantly
greater in the newborn group for serotype 19F only.
The natural rate of decay of anticapsular IgG in the EPI group
between birth and 6 weeks did not vary significantly by serotype,
and the mean decay rate across all 7 serotypes, adjusted for
correlation within individual infants, was 0.168lg/mL/week
(95% CI, 0.163–0.173). Comparing the predicted decline in
anticapsular antibody concentration in the newborn group
against the actual concentrations observed at 10 weeks, newborn
vaccination was estimated to lead to a rise of between 1.5- and
11-fold (median, 2.4-fold), depending on serotype (Table 3).
An analysis of variance of the log ratio rise in IgG before and
after booster immunization at 9 months was significantly greater
following 7vPCV booster than PPV booster for all serotypes
(P, .001) except 19F (Supplementary Figure 1). After adjusting
for booster type, there were no significant differences in response
ratios between the EPI group and the newborn group for any
serotype. Because 7vPCV boosted more effectively, we repeated
this analysis restricting to infants who received 7vPCV; there
were no differences in the response ratios between the vaccine
schedule groups.
To explore the effect of passively transferred maternal anti-
body on response to vaccine, linear regression of the 18-week
serotype-specific GMCs was fitted across quintiles of homolo-
gous cord blood antibody using VWLS (Supplementary Figure 2).
Quintile break points were constant for both vaccine groups.
Significant downward trends were observed against quintiles
for serotypes 6B, 9V, 14, and 19F (P, .02) in the EPI group and
for serotypes 6B, 14, and 23F (P , .001) in the newborn group.
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Figure 1. Flow chart of (A ) mothers attending the Kilifi Ante-natal Clinic passing through study filters to recruitment and of (B ) trial participants in each
vaccine group illustrating losses to follow-up throughout the 37 weeks of the study. *Determining whether a mother was a resident of the Kilifi Health
and Demographic Surveillance System area required a computer search that took approximately 2–10 minutes. Many mothers left at this stage without
waiting to be identified. aThis included 2 pairs of twins.
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The prevalence of pneumococcal carriage was 78% (205/263)
at 18 weeks and 77% (188/244) at 36 weeks. Multiple strains
(.1 serotype) were detected in 21 carriers at 18 weeks and in 16
carriers at 36 weeks. Although at both time points the prevalence
of vaccine-serotype carriage was lower among the EPI group than
among the newborn group, and the prevalence of nonvaccine-
serotype carriage was higher, these differences were not statisti-
cally significant (Figure 4). The prevalence of vaccine-serotype
carriage at 18 weeks was 25% in the EPI group and 31% in the
newborn group (P 5 .28), and the prevalence of nonvaccine-
serotype carriage was 62% in the EPI group and 51% in the
newborn group (P 5 .08) at 36 weeks.
DISCUSSION
To our knowledge, this is the first study to report the safety and
humoral immunogenicity of PCV at birth. The vaccine was safe
and well tolerated. The reactogenicity and safety profiles in this
study were also similar to those described for other PCV for-
mulations elsewhere in Africa [18–21] and among newborns in
Papua New Guinea [22]. The newborn schedule of 7vPCV was
immunogenic at 18 weeks and induced immunological memory,
as indicated by brisk booster responses at 36 weeks, with no
evidence of immunological tolerance.
Tolerance following newborn immunization with conjugate
vaccines has been observed in a single study of protein-
polysaccharide conjugates against Hib. Infants immunized at
birth and at 2 and 6 months were compared with infants im-
munized at 2, 4, and 6 months using a polyribosylribitol
phosphate–outer membrane protein vaccine [10]. Following the
second and third doses, the newborn vaccine group had
Table 2. Numbers and Percentages of Serum Samples With Anti-
Capsular Immunoglobulin G Concentrations ‡0.35 mg/mL at 18
Weeks and 36 Weeks of Age by Vaccine Group
Serotype
EPI group,
proportion (%)
Newborn group,
proportion (%) P
18 weeks
4 133/133 (100) 127/128 (99) .31
6B 122/133 (92) 111/128 (87) .19
9V 130/133 (98) 125/129 (97) .67
14 130/133 (98) 126/129 (98) .97
18C 131/133 (98) 123/129 (95) .14
19F 133/133 (100) 126/127 (99) .31
23F 129/133 (97) 119/129 (92) .09
36 weeks
4 111/124 (90) 95/118 (81) .049
6B 93/124 (75) 93/118 (79) .48
9V 107/124 (86) 91/118 (77) .06
14 118/124 (95) 109/118 (92) .37
18C 74/124 (60) 66/118 (56) .56
19F 113/123 (92) 102/118 (86) .17
23F 83/124 (67) 79/118 (67) .99
Abbreviations: EPI, Expanded Programme on Immunization.
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Figure 2. Geometric mean concentrations (GMCs) of anticapsular
immunoglobulin G (IgG) by vaccine group for 7 serotypes. The figure
shows the geometric mean and 95% confidence intervals of anticapsular
IgG in 2 vaccine groups. At 18 weeks the geometric mean concentrations
in the Expanded Programme on (EPI) group are significantly higher for
4 serotypes; at 36 weeks they are significantly higher for serotype 4 only.
*P , .05; **P , .005.
Table 1. Baseline Characteristics of the Randomized Schedule
Groups
Variable EPI Newborn
Mother’s age, years 28.7 (6.5) 29.8 (6.4)
Birth weight, g 3088 (341) 3137 (412)
Heart rate at evaluation, beats
per minute
127.4 (12.0) 126.7 (11.0)
Respiratory rate at evaluation,
per minute
51.3 (7.0) 51.0 (6.7)
Axillary temperature at evaluation, C 36.7 (0.41) 36.7 (0.43)
Male sex, no. (%) 77 (51.3) 75 (50.0)
Data are mean (standard deviation) unless otherwise specified. Differences
between groups were tested by analysis of variance, except for sex, which
was analyzed by means of the v2 test.
Abbreviations: EPI, Expanded Programme on Immunization.
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significantly lower antibody titers, implying that a birth dose
may tolerize the immune system to subsequent doses of the
same vaccine. Tolerance was not observed in 2 other studies of
Hib conjugate vaccines in newborns [23, 24].
In the present study, anticapsular IgG concentrations at 18
weeks were lower in the newborn group than in the standard EPI
group for 4 of 7 serotypes, but by 36 weeks they were in-
distinguishable for all except serotype 4. We observed reciprocity
between antibody concentrations and function, as measured by
avidity. At both 18 weeks and 36 weeks, avidity was significantly
greater in the newborn group than in the EPI group to some
serotypes. This intriguing finding confirms that immunization
at birth primes the immune system. However, the schedule
design does not allow us to differentiate whether it is age,
time, or dose interval that is responsible for this avidity dif-
ference. Although the effect of maternal antibody has also
been reported to interfere with early life vaccine responses,
in this study several serotype-specific responses in both the
newborn and EPI groups were adversely affected by high levels
of maternal antibodies.
The responses to a booster dose did not differ between
vaccine schedule groups. Similar findings have been observed
in premature infants first immunized with PCV at 2 months of
age [25]. These responses show that 7vPCV administered at
birth does not interfere with the generation of immune
memory to pneumococcal polysaccharides by subsequent
7vPCV doses and thus refute the predictions of immune
tolerance. This is important in developing countries where
pneumococcal transmission is frequent. In Kilifi, half of all
neonates have acquired nasopharyngeal carriage by 27 days of
life [26], and nasopharyngeal exposure in an infant primed by
a birth dose of PCV may lead to boosted immunity rather than
early disease.
Previous studies have shown that a primary series of PCV
reduces the carriage prevalence of vaccine serotypes by half but
has little effect on total pneumococcal carriage [27, 28]. We did
not observe any difference between vaccine schedule groups in
their effect on carriage of vaccine or nonvaccine serotypes at
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Figure 3. Geometric mean avidity indices for anticapsular immuno-
globulin G (IgG) by vaccine group for 4 serotypes. The figure shows the
geometric mean and 95% confidence intervals of the avidity index for
anticapsular IgG in 2 vaccine groups. At 18 weeks, the geometric mean
avidity index in the newborn group are significantly higher for 3
serotypes; at 36 weeks, they are significantly higher for serotype 19F only.
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Table 3. Estimated Response to a First Dose of 7-Valent
Pneumococcal Conjugate Vaccine Given at Birth
Serotype
Decay rate
in lg/mL/week
(EPI group)
Observed concentration
at 10 weeks versus
concentration
predicted from
cord blood
(newborn group),
geometric mean
ratio (95% CI)
4 0.176 10.5 (7.17–15.5)
6B 0.170 1.51 (1.06–2.15)
9V 0.157 3.11 (2.21–4.37)
14 0.142 2.09 (1.52–2.87)
18C 0.182 3.80 (2.66–5.43)
19F 0.185 2.39 (1.82–3.14)
23F 0.153 1.81 (1.22–2.69)
Natural decay rates for IgG were estimated in the cord blood and 6-week
serum samples of the EPI group. The mean decay rate (0.168 lg/mL/week
[95% CI, .163–.173]) did not vary significantly by serotype. The ratio increase
attributable to newborn vaccination was estimated for each infant in the
newborn group as the observed concentration at 10 weeks divided by the
concentration predicted by applying the common decay rate to the cord blood
sample.
Abbreviations: CI, confidence interval; EPI, Expanded Programme on
Immunization.
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either 18 or 36 weeks. Compared with the newborn vaccine
group, the prevalence of vaccine-type carriage in the EPI group
was 6% lower at 18 weeks and 10% lower at 36 weeks. Although
small changes in carriage prevalence may influence herd pro-
tection and serotype replacement disease, the size of the present
study was not sufficient to determine whether newborn vacci-
nation would shape such population effects differentially.
This study provides the empiric basis to support exploratory
immunization of newborns against pneumococcal disease. The
next step is to establish whether the schedule interferes with re-
sponses to other routine immunizations and to explore whether
the second and third doses can also be delivered earlier. Newborn
immunization could be advantageous in settings where an epi-
demiologically significant proportion of IPD occurs before 2
months of age, where vaccine coverage at birth is high, or where
the timing of routine immunization is delayed. Although
American neonates have been shown to benefit from indirect
protection caused by immunization of infants [29], this may not
extend to the serotypes (eg, 5 and 1) that predominate in IPD in
African newborns [8]. Schedules that include a first dose of
7vPCV at birth are safe, immunogenic, and prime for immune
memory and could provide protective antibodies where local
epidemiological characteristics reveal a window of vulnerability
in young infants.
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